Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors
M. Schuller, Tryfon Zarganes‐Tzitzikas, James M. Bennett, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 324-324
Open Access | Times Cited: 13

Showing 13 citing articles:

PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation
Pulak Kar, Chatrin Chatrin, N Mimica Dukic, et al.
The EMBO Journal (2024) Vol. 43, Iss. 14, pp. 2929-2953
Open Access | Times Cited: 15
Exploring pyrazolines as potential inhibitors of NSP3-macrodomain of SARS-CoV-2: synthesis and in silico analysis
R. R. Joshi, Harsh Gaikwad, Bhavana Soge, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Rahul K. Suryawanshi, Priyadarshini Jaishankar, G.J. Correy, et al.
(2025)
Open Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Rahul K. Suryawanshi, Priyadarshini Jaishankar, G.J. Correy, et al.
(2025)
Open Access
Antivirals for Broader Coverage against Human Coronaviruses
Mia Outteridge, Christine M. Nunn, Kevin M. Devine, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 156-156
Open Access | Times Cited: 4
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Rahul K. Suryawanshi, Priyadarshini Jaishankar, G.J. Correy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning
G.J. Correy, Moira Rachman, Takaya Togo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery
Xin Li, Yongcheng Song
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103832-103832
Open Access | Times Cited: 11
An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors
Joseph J. O’Connor, Dana Ferraris, Anthony R. Fehr
Pathogens (2023) Vol. 12, Iss. 10, pp. 1221-1221
Open Access | Times Cited: 7
HTRF-based assay for detection of mono-ADP-ribosyl hydrolyzing macrodomains and inhibitor screening
Niklas Ildefeld, Dieter Steinhilber, Ewgenij Proschak, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110333-110333
Open Access
Synthesis of Structural ADP-Ribose Analogues as Inhibitors for SARS-CoV-2 Macrodomain 1
Koen J. Rijpkema, M. Schuller, Miriam S. van der Veer, et al.
Organic Letters (2024) Vol. 26, Iss. 27, pp. 5700-5704
Open Access
Evolutionary and molecular basis of ADP-ribosylation reversal by zinc-dependent macrodomains
A. Ariza, Qiang Liu, Nathan Cowieson, et al.
Journal of Biological Chemistry (2024), pp. 107770-107770
Open Access
Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication
Jessica J. Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
(2024)
Open Access
Page 1

Scroll to top